If the announcement is made first thing in the morning, I expect it to be favorable for Biogen.
I thought there was going to be a hearing/presentation on Monday, not a decision necessarily.
One of my concerns about FDA's approval of adu* is that it becomes the SOC. Then, if blarcamesine receives approval in a year, will it be the new SOC or only a drug that is better? If the latter, then other drugs that are not a efficient as blarcamesine might be approved as being better than adu* though not Anavex's drug.
IMO, it would be much, much better for Anavex that blarcamesine be the first new SOC rather than a low bar set by adu* that other drugs can hop over though mot as efficient as blarcamsine.
ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!